Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12123860rdf:typepubmed:Citationlld:pubmed
pubmed-article:12123860lifeskim:mentionsumls-concept:C0030567lld:lifeskim
pubmed-article:12123860lifeskim:mentionsumls-concept:C2347026lld:lifeskim
pubmed-article:12123860lifeskim:mentionsumls-concept:C0370003lld:lifeskim
pubmed-article:12123860lifeskim:mentionsumls-concept:C0017337lld:lifeskim
pubmed-article:12123860lifeskim:mentionsumls-concept:C0002198lld:lifeskim
pubmed-article:12123860lifeskim:mentionsumls-concept:C0004083lld:lifeskim
pubmed-article:12123860lifeskim:mentionsumls-concept:C1152596lld:lifeskim
pubmed-article:12123860lifeskim:mentionsumls-concept:C0332125lld:lifeskim
pubmed-article:12123860pubmed:issue1lld:pubmed
pubmed-article:12123860pubmed:dateCreated2002-7-18lld:pubmed
pubmed-article:12123860pubmed:abstractTextAlpha-2 macroglobulin (A2M) is a component of Lewy bodies, a hallmark of Parkinson's disease (PD). In 159 PD patients and 190 normal controls, we studied two A2M polymorphisms by the polymerase chain reaction-restriction fragment length polymorphism method: a five-nucleotide deletion at the 5' splice site of exon 18; and a valine to isoleucine exchange in amino acid position 1000 near the thiolester active site. No significant differences in allelic and genotypic distribution were found between cases and controls or between early and late-onset PD patients. The present data suggest that these polymorphisms do not represent a risk factor for PD and do not modulate the age at onset of PD.lld:pubmed
pubmed-article:12123860pubmed:languageenglld:pubmed
pubmed-article:12123860pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12123860pubmed:citationSubsetIMlld:pubmed
pubmed-article:12123860pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12123860pubmed:statusMEDLINElld:pubmed
pubmed-article:12123860pubmed:monthAuglld:pubmed
pubmed-article:12123860pubmed:issn0304-3940lld:pubmed
pubmed-article:12123860pubmed:authorpubmed-author:NicolettiGius...lld:pubmed
pubmed-article:12123860pubmed:authorpubmed-author:ZappiaMarioMlld:pubmed
pubmed-article:12123860pubmed:authorpubmed-author:AnnesiGraziaGlld:pubmed
pubmed-article:12123860pubmed:authorpubmed-author:QuattroneAldo...lld:pubmed
pubmed-article:12123860pubmed:authorpubmed-author:CaraccioloMan...lld:pubmed
pubmed-article:12123860pubmed:authorpubmed-author:SerraPaoloPlld:pubmed
pubmed-article:12123860pubmed:authorpubmed-author:TomainoCarmin...lld:pubmed
pubmed-article:12123860pubmed:authorpubmed-author:SpadaforaPatr...lld:pubmed
pubmed-article:12123860pubmed:authorpubmed-author:PasquaAngela...lld:pubmed
pubmed-article:12123860pubmed:authorpubmed-author:AnnesiFerdina...lld:pubmed
pubmed-article:12123860pubmed:authorpubmed-author:MessinaDemetr...lld:pubmed
pubmed-article:12123860pubmed:issnTypePrintlld:pubmed
pubmed-article:12123860pubmed:day2lld:pubmed
pubmed-article:12123860pubmed:volume328lld:pubmed
pubmed-article:12123860pubmed:ownerNLMlld:pubmed
pubmed-article:12123860pubmed:authorsCompleteYlld:pubmed
pubmed-article:12123860pubmed:pagination65-7lld:pubmed
pubmed-article:12123860pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:12123860pubmed:meshHeadingpubmed-meshheading:12123860...lld:pubmed
pubmed-article:12123860pubmed:meshHeadingpubmed-meshheading:12123860...lld:pubmed
pubmed-article:12123860pubmed:meshHeadingpubmed-meshheading:12123860...lld:pubmed
pubmed-article:12123860pubmed:meshHeadingpubmed-meshheading:12123860...lld:pubmed
pubmed-article:12123860pubmed:meshHeadingpubmed-meshheading:12123860...lld:pubmed
pubmed-article:12123860pubmed:meshHeadingpubmed-meshheading:12123860...lld:pubmed
pubmed-article:12123860pubmed:meshHeadingpubmed-meshheading:12123860...lld:pubmed
pubmed-article:12123860pubmed:meshHeadingpubmed-meshheading:12123860...lld:pubmed
pubmed-article:12123860pubmed:meshHeadingpubmed-meshheading:12123860...lld:pubmed
pubmed-article:12123860pubmed:meshHeadingpubmed-meshheading:12123860...lld:pubmed
pubmed-article:12123860pubmed:meshHeadingpubmed-meshheading:12123860...lld:pubmed
pubmed-article:12123860pubmed:meshHeadingpubmed-meshheading:12123860...lld:pubmed
pubmed-article:12123860pubmed:meshHeadingpubmed-meshheading:12123860...lld:pubmed
pubmed-article:12123860pubmed:meshHeadingpubmed-meshheading:12123860...lld:pubmed
pubmed-article:12123860pubmed:meshHeadingpubmed-meshheading:12123860...lld:pubmed
pubmed-article:12123860pubmed:meshHeadingpubmed-meshheading:12123860...lld:pubmed
pubmed-article:12123860pubmed:meshHeadingpubmed-meshheading:12123860...lld:pubmed
pubmed-article:12123860pubmed:meshHeadingpubmed-meshheading:12123860...lld:pubmed
pubmed-article:12123860pubmed:year2002lld:pubmed
pubmed-article:12123860pubmed:articleTitleNo evidence of association between the alpha-2 macroglobulin gene and Parkinson's disease in a case-control sample.lld:pubmed
pubmed-article:12123860pubmed:affiliationInstitute of Experimental Medicine and Biotechnology, National Research Council, Mangone (CS), Italy.lld:pubmed
pubmed-article:12123860pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:2entrezgene:pubmedpubmed-article:12123860lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:12123860lld:entrezgene